It is established that nebivolol delivers significant SBP and DBP lowering compared with placebo, whilst outperforming traditional beta-blockers in overall blood pressure normalisation, reinforces nebivolol as an optimal therapeutic choice for managing hypertension across diverse patient groups.
R. Kreutz, B. Rayner, E. Mustapha et al.· European Heart Journal· 0 citations
Patients with chronic coronary syndrome (CCS) frequently experience ongoing angina, diminished quality of life (QoL), and face a heightened need for revascularisation procedures.
The present analysis aimed to consolidate clinical and health economic data regarding the use of ranolazine in CCS. By combining...
P. Collins, W. Alhabeeb, I. Alhaddad et al.· European Heart Journal· 0 citations
Ranolazine provides robust symptomatic and functional benefits in patients with CSA and is associated with modest reductions in MI and revascularization procedures, such as PCI or CABG.
Peter Collins, W. Alhabeeb, Imad Alhaddad et al.· Cureus· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.